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Abstract
Background: Macrophage activation syndrome (MAS) is the secondary hemophagocytic lymphohistiocytosis
associated with rheumatic diseases. Recently, the different cytokine profiles between systemic juvenile idiopathic
arthritis (sJIA)-associated MAS (sJIA-MAS) and juvenile systemic lupus erythematosus (JSLE)-associated MAS (JSLE-MAS)
were reported. However, there is little information about juvenile dermatomyositis (JDM)-associated MAS (JDM-MAS).
Case presentation: A 4-year-old girl with JDM was hospitalized because of fever, erythema, hepatosplenomegaly,
cytopenia, liver dysfunction and coagulopathy. Bone marrow aspiration revealed appreciable numbers of activated and
hemophagocytosing macrophages. She was diagnosed as having JDM–MAS complicated with interstitial pneumonia (IP)
based on the findings of the elevation of serum Krebs von den Lungen-6 (KL-6) levels and chest computed tomography
findings. We analyzed circulating levels of interleukin (IL)-2,4,6,10,18, tumor necrosis factor-α and interferon-γ in the
patient. Hypercytokinemia occurred at the diagnosis of MAS and IP, showing with the prominent elevations of IL-6 and
IL-18 levels. The cytokine profiles were distinct from those reported in patients with sJIA-MAS or JSLE-MAS. High-dose
corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels. Subsequent
cyclophosphamide therapy successfully controlled IP, paralleled with the declining pattern of IL-18 and KL-6 levels.
Conclusion: This is the first report to describe a successful treatment and the cytokine profile of JDM-MAS and IP. Serum
IL-6 and IL-18 levels may be useful for predicting the disease activity of JDM-MAS and IP, respectively.
Keywords: Cytokine, Juvenile dermatomyositis, Macrophage activation syndrome, Autoimmune-associated
hemophagocytic lymphohistiocytosis, Interstitial pneumonia, IL-18, IL-6, KL-6
Background
Macrophage activation syndrome (MAS) is the second-
ary hemophagocytic lymphohistiocytosis (HLH) associ-
ated with rheumatic diseases, which is a life-threatening
complication of systemic inflammatory disorders [1]. It
is clinically characterized by fever, hepatosplenomegaly,
lymphadenopathy, cytopenia, intravascular coagulation
and organ failure [1]. Juvenile dermatomyositis (JDM) is
a multisystem disease of uncertain origin that results in
chronic inflammation of the striated muscle and skin
[2]. Although MAS has been reported to develop in vari-
ous rheumatic diseases, it is most often complicated in
the children with systemic juvenile idiopathic arthritis
(sJIA) [1]. Juvenile systemic lupus erythematosus (JSLE)
is also one of the underlying rheumatic diseases in which
MAS occurs more frequently seen than in the others [3].
On the other hand, MAS is a quite rare complication in
JDM patients [4].
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Recently, the difference in the serum cytokine profiles
between sJIA-associated MAS (sJIA-MAS) and JSLE-
associated MAS (JSLE-MAS) was reported [5]. However,
there have been no reports about the cytokine profiles in
JDM-associated MAS (JDM-MAS) with interstitial pneu-
monia (IP). We present the first report about successful
treatment and analysis of cytokine profile in a case with
JDM complicated MAS and IP.
Case presentation
Case
A previously healthy 4-year-old girl exhibited butterfly
like rash, heliotrope rash, Gottron’s papules, mild prox-
imal muscle weakness, muscle grasping pain, and serum
creatine kinase (CK) levels and erythrocyte sedimentation
rate were elevated. This patient fulfilled the diagnostic cri-
teria for dermatomyositis [6]. To fulfill the criteria,
patients must meet more than 4 findings among 8
(1. proximal muscle weakness, 2. muscle grasping and
spontaneous pain, 3. nondestructive arthritis or arthralgia,
4. elevated CK or aldolase level, 5. presence of systemic
inflammatory signs (fever, elevated C-reactive protein, or
elevated erythrocyte sedimentation rate), 6. myogenic
changes on electromyogram, 7. anti Jo-1 antibody positive,
8. pathologic findings compatible with inflammatory myo-
sitis) with having shown the characteristic skin findings
(heliotrope rash or Gottron’s papules). She was treated
with high-dose oral prednisolone (PSL) followed by 2
courses of methylprednisolone pulse therapy (MPT). Sub-
sequently, the skin rash and myositis gradually improved,
and low-dose oral PSL was continued. Three months
after MPT, she was emergently admitted to our hospital
because of dyspnea, high fever, erythema, hepatospleno-
megaly, cytopenia, liver dysfunction and coagulopathy.
Hypoxemia, high Krebs von den Lungen-6 (KL-6) levels,
and diagnostic imagings indicated progressive IP (Fig. 1a,
b). Results of hematological examinations were as fol-
lows: leukocytes, 2.56 × 109/L; hemoglobin, 13.4 g/dL;
platelet count, 119 × 109/L; D-dimer, 120.0 mg/L (refer-
ence range [rr]: 0–1 mg/L); alanine aminotransferase
(ALT), 596 IU/L (rr: 5–43 IU/L); aspartate aminotrans-
ferase (AST), 1,154 U/L (rr: 12–34 IU/L); ferritin,
8,062 ng/mL (rr: 25–280 ng/mL); lactate dehydrogenase
(LDH), 2,267 IU/L (rr: 115–217 IU/L); CK, 40 IU/L
(rr: 41–123 IU/L); KL-6, 1,106 U/mL (rr: 0–499 U/dL).
The urinary β2-microglobulin (U-β2MG) levels were
elevated, 8.06 mg/L (rr: <0.29 mg/L). The tests for anti-
nuclear antibody (1:80; speckle) and anti-melanoma
differentiation-associated gene 5 (MDA5) antibody were
positive. Anti-Jo-1 antibody and Epstein–Barr virus (EBV)
DNA were negative. Bone marrow aspiration showed acti-
vated macrophages phagocytosing hematopoietic ele-
ments. She was diagnosed as having JDM-MAS, and
progressive IP. Heparinization, dexamethasone palmitate
(DP) and cyclosporine (CsA) therapy appreciably con-
trolled the disease activity. Six days later, the flare-up of
MAS such as decrease of platelet count and elevation of
serum ferritin and U- β2MG levels required MPT for 3
consecutive days, and then successfully subsided (Fig. 2).
The following intravenous cyclophosphamide (IVCY)




Fig. 1 Chest radiograph (a) and computed tomography (b) show focal IP in the lower lobes during the acute phase, and no abnormalities at
4 months (c) and 8 months after the convalescent phase of JDM-MAS and IP (d). Arrow marks indicate focal IP
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We studied serum cytokine profiles in this patient
during the acute (days 4, 6), subacute (day 12) or
convalescent phase (day 50) of JDM-MAS with IP.
Multi-target streaming protein quantitative technology
(BD-Pharmingen Cytometric Bead Array; BD Biosci-
ences, Franklin Lakes, NJ, USA) was used to detect the
serum cytokine levels of interleukin (IL)-2,4,6,10, tumor
necrosis factor-α (TNF- α), and interferon-γ (IFN- γ), fol-
lowing the manufacturer's instructions. The lower detec-
tion limits for IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ
were 2.6, 2.6, 2.5, 2.8, 2.8, and 7.1 pg/mL, respectively.
Serum levels of IL-18 were determined using enzyme-
linked immunosorbent assay (ELISA) kits (Medical &
Biological Laboratories, Co., Ltd., Nagoya, Aichi, Japan) ac-
cording to the manufacturer's protocols. The lower detec-
tion limit was 12.5 pg/mL.
The clinical courses and the results of cytokine expres-
sions in our patient with JDM-MAS and IP are shown in
Fig. 2a, b. There was hypercytokinemia before the treat-
ment and during the acute phase of JDM-MAS with IP.
Fig. 2 Sequential changes of the laboratory data and serum cytokine levels during the initial (a), and the overall treatment courses (b). IL-6 (♦), IL-18
(□) and KL-6 (■) were at higher levels at the onset of JDM-MAS and IP. Pearson correlation coefficient test indicated positive correlation of KL-6 with IL-18
(r = 0.997, P<0.01), but not IL-6 or the other cytokine levels. CsA cyclosporine A, DP dexamethasone palmitate, MPT methylprednisolone pulse therapy,
PSL prednisolone, IVCY intravenous cyclophosphamide, U-β2MG urinary β2-microglobulin, IL interleukin, TNF-α tumor necrosis factor-α, IFN-γ interferon-γ
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IL-6 and IL-18 were at prominent high levels compared
with the elevated levels of IL-10, TNF-α and IFN- γ.
IL-6 levels promptly decreased after the initial therapy.
IL-18 levels sustained to be high after the start of effect-
ive treatments during the acute and subacute phases of
JDM-MAS. On the other hand, the IL-18 levels de-
creased after IVCY therapy, in concert with the declining
KL-6 levels and the clinical and radiographical improve-
ment of IP (Fig. 2b).
Discussion
There has been no report about the cytokine profile in
JDM-MAS with IP. To our knowledge, only 5 patients
with JDM-MAS were reported [4, 7–10]. There were 4
boys and 1 girl, the median age of whom was 12 years
ranging from 7 to 14. MAS is a life-threatening condi-
tion, and the reported mortality rates reach 20 % [11].
On the other hand, all 6 patients including ours survived
JDM-MAS after immunosuppressive therapy. The dis-
tinct changes between IL-6 and IL-18 levels during the
treatment come of our patient may indicate the unique
pathophysiology of JDM-driven complications.
Serum IL-18 concentrations in sJIA-MAS patients were
reportedly higher than those seen in EBV-associated HLH
(EBV-HLH) [12]. Monitoring the cytokine profile, includ-
ing IL-18, may be useful for the differential diagnosis of
sJIA-MAS from the other MAS/HLH. Although various
proinflammatory cytokines are overexpressed in MAS pa-
tients, the prodominant elevations of TNF-α levels might
be characteristic as shown in a patient with JSLE-MAS,
compared to sJIA-MAS and EBV-HLH patients [5]. The
cytokine profiles in MAS patients are considered to de-
pend on the underlying rheumatic diseases. In the present
case, both levels of IL-6 and IL-18 were prominently in-
creased during the acute phase of JDM-MAS with IP be-
fore treatment. The serum levels of IL-18 may be
associated with the disease activity of IP, but not JDM-
MAS. Because Pearson correlation coefficient test indi-
cated the positive correlation between serum KL-6 and
IL-18 levels (r = 0.997, P <0.01) (Fig. 2b), we speculated
that the leading cytokine may be IL-18 in sJIA-MAS,
TNF-α in JSLE-MAS, and IL-6 in JDM-MAS, respectively.
Serum IL-18 and TNF-α levels were dominantly elevated
in patients with sJIA-MAS (average of 5 cases) and JSLE-
MAS (one case), respectively (sJIA-MAS IL-18: >100,000,
TNF-α: 0–10, IL-6: 10–50 pg/mL, JSLE-MAS, IL-18:
1,000–3,000, TNF-α: > 1,000, IL-6: 100–500 pg/mL) [5,
12]. IL-18 may be dominant cytokine in sJIA-MAS com-
pared with JSLE-MAS and JDM-MAS. In our patient with
JDM-MAS, the elevation of IL-18 and TNF-α levels was
mild, compared with sJIA-MAS and JSLE-MAS. Serum
IL-6 levels may reflect the disease activity of JDM-MAS.
Further studies are needed to determine the distinct cyto-
kine profile of MAS according to the underlying disease.
Our results suggest that IL-6 and IL-18 may play dif-
ferential roles in the pathophysiology of JDM-MAS and
IP, respectively. It has been reported that activated mac-
rophages and monocytes produce proinflammatory cyto-
kines, such as IL-6, TNF-α in MAS patients. On the
other hand, IL-18 is produced not only from tissue-
resident macrophages and bone marrow macrophages,
but also from dendritic cells in the muscle, and lungs in
patients with JDM [13]. In the present case, there was a
positive correlation between serum IL-18 and KL-6 levels
(Fig. 2b). In IP complicated with JDM, IL-18 is mainly pro-
duced from activated alveolar macrophages, and KL-6 is
produced from type II pneumocytes and bronchial epithe-
lial cells during regeneration of lung tissues [13]. The kin-
etics of these biomarkers may represent the tissues injury
and regeneration occurring in the lungs of IP patients.
Conclusion
This is the first report to describe the successful treat-
ment and the cytokine profile in JDM-MAS with IP pa-
tient. Our results suggest that the elevations of serum
IL-6 and IL-18 levels are associated with disease activity
of JDM-MAS and IP, respectively. These results indicate
that IL-6 and IL-18 may be useful for predicting treat-
ment responsiveness in the pathophysiology of JDM-
MAS with IP. However, the limitation of the present
study is a single case analyzed. Therefore, the accumula-
tion of further case reports is necessary for identifying
the pathophysiology of JDM-MAS.
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